Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

General Biologicals Corporation (GBC)

General Biologicals Corp. (GBC), founded in 1984, is the industry-leading in-vitro diagnostic device manufacturer in ... read more Featured Products: More products

Download Mobile App





General Biologicals Unveils CTC Cancer Detection Products and Automated Molecular System

By LabMedica International staff writers
Posted on 26 Jul 2023

General Biologicals Corporation (GBC, Hsinchu, Taiwan) is introducing two CellBio circulating tumor cell (CTC) cancer detection products at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo, taking place from July 23-27 in Anaheim, California. More...

GBC is officially entering the U.S. market with its award-winning brand, featuring a highly competitive niche In Vitro Diagnostic (IVD) device and assay.

GBC's pair of CTC detection systems, recognized globally as cutting-edge devices, offer rapid, accessible, and affordable diagnostic solutions for early detection, treatment validation, and therapy monitoring. The CellBio platform employs GBC's proprietary iFiltration technology to provide positive control and guarantee filtration accuracy, leading to Taiwan's first standardized CTC system. This patented technology won the 2022 Taiwan National Innovation Award.

The CellBio system offers several advantages including high specificity, sensitivity, and cancer capture rate from 7.5-mL blood samples, delivering results within 90 minutes. The system is applicable to cancer screening, diagnosis, monitoring, and prognosis; it offers optimal treatment and enhances patients' quality of life. During the non-invasive sampling process, the number of CTCs in the blood can be fully monitored, and the system's capture rate of over 90% of cancer cells surpasses the industry standard. The CellBio FX10 accommodates 10 samples simultaneously and features a full-color touch screen, while the CellBio a2000 can handle two samples at a time in compact labs. With over 8,000 samples already processed, GBC has demonstrated strong efficacy.

Alongside CTC systems, GBC is launching its automated all-in-one molecular system, GB RealQuant AIO. This integrated instrument combines extraction, amplification, and detection, delivering fast and reliable results within two hours with high flexibility. The system is compatible with all GB RealQuant HBV, HCV, and HPV Kits.

“CellBio focuses on the detection, monitoring and treatment of cancer metastasis. The goal of GBC is to revolutionize the detection and treatment of cancer through its unique CTC technology and complementary therapeutics platform CellBio,” said Frank Lin, the President of GBC. “More than 10 million patients die from cancer each year and more than 90 percent of the deaths are attributed to metastasis. Currently, there are no approved therapies that specifically target the metastatic process. Targeting CTCs with novel therapeutics could likely have a significant impact on cancer metastases and patient outcome.”

Related Links:
GBC 


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Automated MALDI-TOF MS System
EXS 3000
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: The partnership between OGT and QIAGEN unlocks a complete sample to report workflow for SureSeq NGS panels (Photo courtesy of OGT)

Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation

In clinical research, next-generation sequencing (NGS) panels provide essential insights for genetic analysis, but many laboratories face challenges in transforming raw sequencing data into clinically... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.